1. Home
  2. DERM vs CRBP Comparison

DERM vs CRBP Comparison

Compare DERM & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DERM

Journey Medical Corporation

HOLD

Current Price

$5.07

Market Cap

135.3M

Sector

Health Care

ML Signal

HOLD

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$10.97

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DERM
CRBP
Founded
2014
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.3M
147.4M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
DERM
CRBP
Price
$5.07
$10.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$12.67
$45.50
AVG Volume (30 Days)
154.6K
287.7K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
34.72
N/A
EPS
N/A
N/A
Revenue
$61,858,000.00
$4,822,272.00
Revenue This Year
$39.72
N/A
Revenue Next Year
$63.24
$116.00
P/E Ratio
N/A
N/A
Revenue Growth
10.20
97.62
52 Week Low
$4.31
$6.73
52 Week High
$9.56
$20.56

Technical Indicators

Market Signals
Indicator
DERM
CRBP
Relative Strength Index (RSI) 41.85 63.40
Support Level $4.85 $9.32
Resistance Level $5.50 $11.64
Average True Range (ATR) 0.27 0.69
MACD 0.07 0.04
Stochastic Oscillator 41.82 75.81

Price Performance

Historical Comparison
DERM
CRBP

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: